Your browser doesn't support javascript.
loading
Characteristics of Early Paget's Disease in SQSTM1 Mutation Carriers: Baseline Analysis of the ZiPP Study Cohort.
Cronin, Owen; Subedi, Deepak; Forsyth, Laura; Goodman, Kirsteen; Lewis, Steff C; Keerie, Catriona; Walker, Allan; Porteous, Mary; Cetnarskyj, Roseanne; Ranganath, Lakshminarayan R; Selby, Peter L; Hampson, Geeta; Chandra, Rama; Ho, Shu; Tobias, Jon H; Young-Min, Steven A; McKenna, Malachi J; Crowley, Rachel K; Fraser, William D; Tang, Jonathan; Gennari, Luigi; Nuti, Rannuccio; Brandi, Maria-Luisa; Del Pino-Montes, Javier; Devogelaer, Jean-Pierre; Durnez, Anne; Isaia, Giovanni Carlo; Di Stefano, Marco; Rubio, Josep Blanch; Guanabens, Nuria; Seibel, Markus J; Walsh, John P; Kotowicz, Mark A; Nicholson, Geoffrey C; Duncan, Emma L; Major, Gabor; Horne, Anne; Gilchrist, Nigel L; Ralston, Stuart H.
Afiliação
  • Cronin O; Rheumatic Diseases Unit, Western General Hospital, Edinburgh, UK.
  • Subedi D; Department of Radiology and Nuclear Medicine, Western General Hospital, Edinburgh, UK.
  • Forsyth L; Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Nine Edinburgh Bioquarter, Edinburgh, UK.
  • Goodman K; Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Nine Edinburgh Bioquarter, Edinburgh, UK.
  • Lewis SC; Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Nine Edinburgh Bioquarter, Edinburgh, UK.
  • Keerie C; Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Nine Edinburgh Bioquarter, Edinburgh, UK.
  • Walker A; Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Nine Edinburgh Bioquarter, Edinburgh, UK.
  • Porteous M; South East Scotland Molecular Genetics Service, Western General Hospital, Edinburgh, UK.
  • Cetnarskyj R; School of Health Sciences, University of Dundee, Kirkcaldy, UK.
  • Ranganath LR; Department of Clinical Biochemistry and Metabolic Medicine, The University of Liverpool, UK.
  • Selby PL; Department of Medicine, Manchester Royal Infirmary, Manchester, UK.
  • Hampson G; Department of Chemical Pathology and Metabolic Bone Clinic, Department of Rheumatology, Guy's and St. Thomas' Hospital, London, UK.
  • Chandra R; Clinical Biochemistry, King's College Hospital, London, UK.
  • Ho S; The Robert Jones and Agnes Hunt Orthopaedic and District Hospital, Oswestry, UK.
  • Tobias JH; Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
  • Young-Min SA; Department of Rheumatology, Queen Alexandra Hospital, Cosham, UK.
  • McKenna MJ; Endocrinology Department, St. Vincent's University Hospital, Dublin, Republic of Ireland.
  • Crowley RK; St Vincent's University Hospital and University College Dublin, Dublin, Republic of Ireland.
  • Fraser WD; Endocrinology Department, St. Vincent's University Hospital, Dublin, Republic of Ireland.
  • Tang J; St Vincent's University Hospital and University College Dublin, Dublin, Republic of Ireland.
  • Gennari L; Norwich Medical School, Faculty of Medicine and Health Sciences, University of East Anglia, Norwich, UK.
  • Nuti R; Norwich Medical School, Faculty of Medicine and Health Sciences, University of East Anglia, Norwich, UK.
  • Brandi ML; Department of Medicine, Surgery and Neurosciences, University of Sienna, Sienna, Italy.
  • Del Pino-Montes J; Department of Medicine, Surgery and Neurosciences, University of Sienna, Sienna, Italy.
  • Devogelaer JP; Department of Internal Medicine, University Hospital of Careggi, Florence, Italy.
  • Durnez A; Rheumatology Department, University Hospital of Salamanca, Salamanca, Spain.
  • Isaia GC; Clinique Universitaires Saint-Luc, Brussels, Belgium.
  • Di Stefano M; Clinique Universitaires Saint-Luc, Brussels, Belgium.
  • Rubio JB; Geriatrics and Metabolic Bone Diseases, AOU San Giovanni Battista di Torino Corso, Torino, Italy.
  • Guanabens N; Geriatrics and Metabolic Bone Diseases, AOU San Giovanni Battista di Torino Corso, Torino, Italy.
  • Seibel MJ; Hopital del Mar, Barcelona, Spain.
  • Walsh JP; Department of Rheumatology, Hospital Clinic, CIBERehd, Barcelona, Spain.
  • Kotowicz MA; Department of Endocrinology and Metabolism, Concord Repatriation General Hospital, Sydney, Australia.
  • Nicholson GC; Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Nedlands, Australia.
  • Duncan EL; Medical School, The University of Western Australia, Crawley, Australia.
  • Major G; Department of Endocrinology and Diabetes, Deakin University, Geelong, Australia.
  • Horne A; Rural Clinical School Research Centre, Darlin Heights, The University of Queensland, Brisbane, Australia.
  • Gilchrist NL; Endocrinology Department, Royal Brisbane and Woman's Hospital, Herston, Australia.
  • Ralston SH; Translational Genomics Group, Institute of Health and Biomedical Innovation, Faculty of Health, Queensland University of Technology, Translational Research Institute, Princess Alexandra Hospital, Woolloongabba, Australia.
J Bone Miner Res ; 35(7): 1246-1252, 2020 07.
Article em En | MEDLINE | ID: mdl-32176830
ABSTRACT
Mutations in SQSTM1 are strongly associated with Paget's disease of bone (PDB), but little is known about the clinical characteristics of those with early disease. Radionuclide bone scans, biochemical markers of bone turnover, and clinical characteristics were analyzed in SQSTM1 mutation carriers who took part in the Zoledronic acid in the Prevention of Paget's disease (ZiPP) study. We studied 222 individuals, of whom 54.9% were female, with mean ± SE age of 50.1 ± 0.6 years. Twelve SQSTM1 mutations were observed, including p.Pro392Leu, which was present in 141 of 222 (63.5%) subjects. Bone scan examination revealed evidence of PDB in 20 subjects (9.0%), ten of whom (50%) had a single affected site. Participants with lesions were older than those without lesions but the difference was not significant (53.6 ± 9.1 versus 49.8 ± 8.9; p = .07). The mean age of participants with lesions was not significantly different from the age at which their parents were diagnosed with PDB (55 years versus 59 years, p = .17). All individuals with lesions were asymptomatic. Serum concentrations of total alkaline phosphatase (ALP) normalized to the upper limit of normal in each center were higher in those with lesions (0.75 ± 0.69 versus 0.42 ± 0.29 arbitary units; p < .0001). Similar findings were observed for other biochemical markers of bone turnover, but the sensitivity of ALP and other markers in detecting lesions was poor. Asymptomatic PDB is present in about 9% of SQSTM1 mutation carriers by the fifth decade. Further follow-up of this cohort will provide important information on the natural history of early PDB and its response to treatment. © 2020 The Authors. Journal of Bone and Mineral Research published by American Society for Bone and Mineral Research.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Osteíte Deformante / Proteínas Adaptadoras de Transdução de Sinal / Proteína Sequestossoma-1 Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged Idioma: En Revista: J Bone Miner Res Assunto da revista: METABOLISMO / ORTOPEDIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Osteíte Deformante / Proteínas Adaptadoras de Transdução de Sinal / Proteína Sequestossoma-1 Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged Idioma: En Revista: J Bone Miner Res Assunto da revista: METABOLISMO / ORTOPEDIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Reino Unido